XLXiaozhi Liu

Xiaozhi Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaozhi Liu has a total of 228 co-authors. Here are the top co-authors by number of shared publications:

  • Xiyun Bian

    Tianjin Key Laboratory of Epigenetics for Organ Development in Preterm Infants The Tianjin Fifth Central Hospital, Binhai Tianjin China

    13 shared publications
  • Yanxia Li

    Central Laboratory, Tianjin Key Laboratory of Epigenetic for Organ Development of Preterm Infants, Tianjin Fifth Central Hospital, Tianjin, PR China

    11 shared publications
  • Xiaofang Ma

    Tianjin Key Laboratory of Epigenetics for Organ Development of Preterm Infants Tianjin fifth Central Hospital Tianjin 300450 China

    10 shared publications
  • Chunyan Zhang

    Department of General Surgery, Tianjin Fifth Central Hospital

    8 shared publications
  • Lili Li

    Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China

    5 shared publications
  • Chunyan Zhang

    Department of General Surgery, Tianjin Fifth Central Hospital

    4 shared publications

Latest Publications

  • Open Access

    Structural molecule–associated protein changes in SUMO1-deficient mice are associated with attenuated age-related anxiety-like behavior

    by Hongbin Xu, Yuxiang Wang, Xiaozhi Liu, Qiwei Dai, Yanxia Li, He Dong, Fang Nie, Lianxue Zhang, Liang Wang, Cao Ma, et al.

  • Open Access

    Ginsenoside Rg3 promotes chemosensitivity in lung adenocarcinoma organoids via apoptotic pathways

    by Min Liu, Yanxia Li, Bing Han, Ni Zeng, Xiuhua Wei, Xiaoli Xing, Zhongmin Jiang, Xiaozhi Liu, Chunyan Zhang

    Introduction: Platinum-based chemotherapy remains a cornerstone for advanced non-small cell lung cancer (NSCLC), but its efficacy is often compromised by chemoresistance, necessitating strategies to restore drug sensitivity. Ginsenoside Rg3, an active component of Panax ginseng, exhibits anti-tumor and potential chemosensitizing properties, though its mechanisms in clinically relevant models are not fully understood. Methods: We successfully established and characterized three lung adenocarcinoma patient-derived organoid (PDO) lines that faithfully recapitulated the histopathological and molecular features of the parental tumors. The chemosensitizing effect of Rg3 on cisplatin was evaluated by assessing organoid viability, half-maximal inhibitory concentration (IC50), intracellular reactive oxygen species (ROS) levels, and apoptosis via TUNEL assay. Results: Pharmacodynamic evaluation revealed that the combination of Rg3 and cisplatin exerted superior inhibitory effects on organoid viability compared to either agent alone, with a pronounced reduction in IC50. Furthermore, the combination treatment significantly increased intracellular ROS levels and induced apoptosis, as evidenced by TUNEL assay. Discussion: This study provides preclinical evidence for Rg3 as a promising chemosensitizer in lung adenocarcinoma and highlights the value of PDOs as a robust platform for personalized drug response profiling. These findings support further exploration of Rg3 as an adjunct to platinum-based chemotherapy in overcoming chemoresistance.


  • Open Access

    Tu-Si-Zi-Wan reduces D-galactose-induced hepatic and cerebral oxidative damage in aging mice via the Nrf2/ARE pathway

    by Guoping He, Di Wu, Juanjuan Wang, Lei Zhang, Chunyan Zhang, Xiaozhi Liu, Xiangli Han

    The global aging population necessitates safe, multi-target strategies to combat age-related functional decline. Tu-Si-Zi-Wan (TSZW), a classical medicinal-dietary formula documented in ancient Chinese medical texts and composed of Cuscuta chinensis and Dioscorea opposita, demonstrates multitargeted potential, yet its systemic antiaging mechanisms remain unclear. This study investigated the protective effects of TSZW on hepatic and neurological aging through the Nrf2/ARE pathway while exploring its systemic impact on metabolic and immune homeostasis. Firstly, network pharmacology predicted the targets and pathways of TSZW, identifying 113 shared TSZW-aging targets, with Nrf2, IL-6, and HIF-1α as core nodes enriched in oxidative stress-related pathways. Secondly, a D-galactose-induced aging mouse model was established, followed by 4 months of TSZW intervention (low, medium, and high doses). Behavioral tests (open field, novel object recognition, and grip strength), metabolic and inflammatory marker detection, histopathology, and molecular analyses (western blot, quantitative PCR, and immunofluorescence) were used to assess systemic aging phenotypes, oxidative damage, and Nrf2/ARE pathway activity. TSZW dose-dependently improved motor activity, cognition, and muscle strength; restored liver/kidney function (ALT, AST, Cr, and urea); reduced the serum levels of tumor necrosis factor-α, interleukin 6, and interleukin-1β; and attenuated hepatic/neuronal damage. It suppressed the expression of senescence markers (p16, p21, and p53) while increasing the expression of antioxidant enzymes (SOD and GSH-Px) and reducing oxidative damage (MDA and ROS). Mechanistically, TSZW promoted Nrf2 nuclear translocation; upregulated Hmox1, Nqo1, and Gclm expression; and inhibited Keap1. Notably, high-dose TSZW outperformed vitamin E in reversing immune organ atrophy (thymus and spleen indices) and preserving hippocampal neurons. Collectively, TSZW alleviates hepatic and neurological aging via Nrf2/ARE-mediated antioxidant signaling, with concurrent mitigation of systemic aging phenotypes, including immune organ atrophy and chronic inflammation. Its multicomponent synergy highlights Traditional Chinese medicinal cuisine's potential for systemic anti-aging intervention by targeting oxidative stress-inflammation-metabolic signaling crosstalk.

  • Open Access

    Transcriptional coordination in multicellular lineage differentiation during lung organogenesis: deciphering the role of epithelial cells as a microenvironmental regulatory hub

    by Chunyan Zhang, Jin Liu, Yanxia Li, Bing Han, Min Liu, Jie Zheng, Xiaozhi Liu

    Lung development is a complex and precisely regulated process of continuously branching morphogenesis, the core of which lies in the directed differentiation of diverse cell types and the dynamic intercellular interaction network. This review systematically delineates the differentiation pathways of major cellular lineages during pulmonary development, with a particular focus on the dual functions of epithelial cells as the core regulatory hub of the microenvironment. These cells not only dominate the spatial patterning of lung branching morphogenesis but also orchestrate the developmental fates of key cell types through multiple signaling cues. Furthermore, this review discusses the regenerative properties of lung-resident stem cells and the interaction patterns between various cell types and epithelial cells. These insights not only provide an important theoretical framework for elucidating the molecular regulatory network of lung development but also offer novel ideas for the optimization of strategies in lung regenerative medicine and the precision intervention for lung-related diseases.

  • Open Access

    Molecular subtype-specific breast cancer organoids: development of an FGF-free estradiol valerate culture system for precision drug screening

    by Chunyan Zhang, Bing Han, Zhihua Jia, Min Liu, Yanxia Li, Jie Xu, Jie Zheng, Yajing Sun, Yuting Le, Shupeng Zhang, et al.

    Breast cancer, a prevalent malignancy among women, exhibits high heterogeneity, highlighting the critical need for personalized treatment strategies. Breas


  • Open Access

    Saikosaponin D Induced Apoptosis and Anti-Tumor Effect Enhancing Chemotherapy Sensitivity of Gemcitabine in Patient-Derived Cholangiocarcinoma Organoids

    by Bing Han, Guoqiang Xing, Kunkun Du, Yanxia Li, Min Liu, Jie Zheng, Shoufeng Wang, Canming Li, Shupeng Zhang, Chunyan Zhang, et al.

    Background: Cholangiocarcinoma (CCA), an aggressive malignancy with limited therapeutic options and poor survival rates, poses an urgent clinical challenge necessitating innovative therapeutic strategies. Saikosaponin D (SSd), a bioactive compound derived from Bupleurum, has demonstrated anticancer potential in various malignancies. However, its role in CCA remains unexplored. This study investigated the antitumor effects and potential mechanisms of SSd, both alone and in combination with gemcitabine, utilizing patient-derived cholangiocarcinoma organoids (PDCOs). Methods: Four PDCO models were established from surgical tumor tissues and metastatic ascites of CCA patients. Histological, immunohistochemical (Cytokeratin 7, Cytokeratin 19 and Ki-67), and immunofluorescence analyses validated the fidelity of organoids to the primary tumors. Drug sensitivity testing evaluated SSd (0.001– 50μM) and gemcitabine alone or in combination (ratios 1:1, 1:2, 1:4) using dose-response curves and combination index (CI) analysis. Apoptosis mechanisms were assessed via TUNEL staining, caspase-3 activity assays, and the JC-1 assay for the mitochondrial membrane potential. Results: SSd exhibited dose-dependent growth inhibition across PDCOs, with half-maximal inhibitory concentration (IC50) values ranging from 0.9μM to 13μM. Gemcitabine showed IC50 values spanning 0.03μM to 11.1μM. Notably, the SSd-gemcitabine combination at 1:4 ratio demonstrated synergistic effects (CI=0.0005), significantly reducing organoid viability. Ascites-derived PDCOs (eg, CCA182) displayed lower sensitivity to SSd, correlating with prior chemotherapy exposure. Apoptosis induction by SSd was confirmed through increased TUNEL-positive cells, elevated caspase-3 activity, and mitochondrial depolarization. Histological and molecular profiles of PDCOs closely mirrored those of the primary tumors, preserving spatial heterogeneity (eg, glandular structures in tissue-derived PDCOs vs compact morphology in ascites-derived models). Conclusion: The combination of SSd and gemcitabine exerts a synergistic antitumor effect in patient-derived cholangiocarcinoma organoids through activating caspase-3 and triggering mitochondrial dysfunction-mediated apoptosis.

  • Myeloma interaction with bone marrow stromal cells suppresses ciliogenesis and osteogenic potential in myeloma bone disease

    by Ying Xie, Zhaoyun Liu, Qian Li, Tiantian Li, Jing Guo, Meilin Hu, Jiantao Sun, Hongmei Jiang, Jingya Wang, Sheng Wang, et al.

    Myeloma bone disease, a complication of multiple myeloma (MM), is characterized by impaired osteogenic function of bone marrow stromal cells (BMSCs) and can be an indicator of disease progression. The underlying mechanisms driving BMSC dysfunction are not yet fully understood. This work investigated MM cell interaction with BMSCs, finding that BMSC ciliogenesis is inhibited in the presence of myeloma cells. We demonstrated that direct interaction between myeloma cells and BMSCs through CD40-CD40L led to BMSC down-regulation of sentrin-specific protease 1 (SENP1), a cysteine protease that removes small ubiquitin-like modifier (SUMO) posttranslational modifications. SENP1 down-regulation led to increased SUMOylation of oral-facial-digital syndrome type 1 protein (OFD1), a centriole and centriolar satellite protein, at K931. Increased SUMOylation led to increased OFD1 protein stability and localization at centriolar satellites of primary cilia and decreased ciliogenesis. Consequently, BMSCs lacking primary cilia became desensitized to shear stress stimulation and decreased Hedgehog signaling activation. This cascade of events resulted in inhibited ciliogenesis and osteogenesis in myeloma-BMSC–interacting models, in Prx1 Cre Cd40l f/f mice, and in clinical samples. Treatment with an anti-CD40 neutralizing antibody effectively mitigated bone disruption and tumor burden in the Vk*MYC and SCID (severe combined immunodeficient)–hu mouse models of MM. Overall, our study provides experimental insights into BMSC dysfunction in MM and suggests that targeting the CD40-SENP1-OFD1 axis could hold promise for MM treatment in clinical settings.


  • Open Access

    Downregulation of SENP1 impairs nuclear condensation of MEF2C and deteriorates ischemic cardiomyopathy

    by Ying Xie, Qiaoyuan Li, Xiyun Bian, Yan Yin, Zhuo Liang, Xu Liu, Tao Zhang, Xiaozhi Liu, Xin Quan, Yunlong Wang

    Ischemic cardiomyopathy (ICM) is characterised by the insufficient capacity of the heart to effectively pump blood, which ultimately contributes to heart failure (HF). In this study, the down regulation of SENP1 is identified in the cardiomyocyte of ICM mouse models and in patients. The depletion of SENP1 exacerbates hypoxia‐induced apoptosis of cardiomyocytes in vitro and deteriorated cardiomyocyte injury of ICM mice in vivo. Mechanistically, SENP1 deSUMOylates the SUMO2‐mediated modification of MEF2C at lysine 401 for stabilising protein stability. Moreover, the interaction with SENP1 controls the nuclear condensation of MEF2C to promote the expression of genes critical for cardiomyocyte function. When rescuing SENP1 expression using adeno‐associated virus serotype 9, the attenuation of cardiomyocyte injury is discerned in the mouse model of ICM. Therefore, these finding elicits a previously unrecognised role and mechanism of SENP1 in safeguarding cardiomyocyte in ICM progression while establishing a basis for the development of SENP1 as a potential marker for ICM diagnosis and treatment.Key points: SNEP1 is downregulated in the cardiomyocyte of ICM mouse models and in patients. SENP1 deSUMOylates the SUMO2‐mediated modification of MEF2C at lysine 401 for protein stability. The interaction with SENP1 controls the nuclear condensation of MEF2C to promote cardiomyocyte function. Cardiac rescue of SENP1 alleviates ischemic heart injury in ICM mouse models by AAV9.


  • Cascaded diffusion-driven self-reinforced adhesive hydrogels for hydrophobic tissue closure

    by Wenyue Xie, Zhuoling Tian, Rui Xue, Xiaocen Duan, Zuoying Yuan, Zhuo Wan, Xing Su, Yuting Feng, Ying Jiang, Hao Wang, et al.